The Business Cocktail

GBT, Syros; Takeda, Cevance collaborates; IND application to ZN-c3

Articles, Business Consultant, DelveInsight's Indication Pipeline Reports, Notizia, Pharma Consultant, The Business Cocktail

Global Therapeutics and Syros Pharmaceuticals have teamed up to move forward to discover, develop and market novel Sickle cell disease and...

Read More

Wave Life Sciences stocks implode; Amarin’s VASCEPA approval; GSK seeks approval

Business Consultant, DelveInsight's Drug Report, Pharma Consultant, The Business Cocktail

Wave Life Sciences has recently announced the discontinuation of its drug suvodirsen, for the treatment of a rare Duchenne Muscular...

Read More

Acquisition of ArQule; Synthorx; and Zentalis nabs a raise

Business Consultant, DelveInsight's Drug Report, Notizia, Oncology based Indications, Pharma Consultant, The Business Cocktail

Merck is set to complete the already planned purchase of the ArQule for USD 2.7 Billion. Under the terms of the agreement, Merck will pay...

Read More

Novartis buys Medicines Co. for USD 9.7 Billion

Business Consultant, DelveInsight's Indication Pipeline Reports, Notizia, Pharma Consultant, The Business Cocktail

Novartis plans to buy The Medicines Company for USD 9.7 Billion to gain access to a heart drug inclisiran, almost ready to get into the...

Read More

GHO to advance healthcare in Europe; Truvian nets USD 27.1 Mn; Lilly plans its diabetes portfolio expansion

Business Consultant, DelveInsight's Indication Pipeline Reports, Notizia, Pharma Consultant, The Business Cocktail

Global Healthcare Opportunities (GHO) Capital, a London-based healthcare investment firm, has recently netted USD 1.1 Billion to advance...

Read More
Close